Loading clinical trials...
Loading clinical trials...
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma: an Observational Retrospective Multicenter Study
The study is designed to describe the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting.
The treatment of Mycosis Fungoides (MF)/Sézary Syndrome (SS) is based on a multimodal approach through the involvement of different specialists including hematologists, dermatologists, and radiation therapists. The approach to the treatment combines different skin directed and systemic therapies (such as chemotherapies, immunomodulating agents, immunotherapies). Although there are several well recognized therapies for the treatment of MF/SS, curative therapies are still needed. In this scenario, effective treatments that provide long term responses and disease control are still lacking. Also, International guidelines (EORTC 2017, ESMO 2018, BAD2018, NCCN) report treatment options for the different stages without recommendations of any order due to lack of evidence from clinical trials. This study is designed to analyze the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
AOU Ospedali Riuniti delle Marche - Clinica di Ematologia
Ancona, Italy
IRCCS Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia
Bari, Italy
U.O.C. Dermatologia e Venereologia Universitaria - A.O.U. Policlinico Consorziale
Bari, Italy
Policlinico S.Orsola-Malpighi - Istituto di Ematologia
Bologna, Italy
ASST Spedali Civili di Brescia - S.C. Ematologia
Brescia, Italy
A.O. Brotzu Ospedale Businco - S.C. Ematologia e CTMO
Cagliari, Italy
A.O.U. Policlinico S. Marco - U.O.C. di Ematologia
Catania, Italy
Unità funzionale di Ematologia - Azienda Ospedaliera Universitaria Careggi
Florence, Italy
S.C. Dermatologia - E.O. Galliera
Genova, Italy
Oncoematologia - ASST Fatebenefratelli - Sacco
Milan, Italy
Start Date
February 27, 2025
Primary Completion Date
July 1, 2026
Completion Date
July 1, 2026
Last Updated
December 2, 2025
400
ESTIMATED participants
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Collaborators
NCT07356245
NCT06470451
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions